Ross S. Francis

Ross S. Francis

Auto-generated profile, based on publicly available information

Ross S. Francis

Department of Kidney and Transplant Services Princess Alexandra Hospital Brisbane Queensland Australia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Clinical Microbiology Reviews
Verified
Journal Article
Open access
PDF file
GAGeorge R. Ambalathingal
George R. Ambalathingal
RFRoss S. Francis
Ross S. Francis
MSMark J. Smyth
Mark J. Smyth
CSCorey Smith
Corey Smith
RKRajiv Khanna
Rajiv Khanna
SUMMARY BK polyomavirus (BKV) causes frequent infections during childhood and establishes persistent infections within renal tubular cells and the uroepithelium, with minimal clinical implications. However, reactivation of BKV in immunocompromised individuals following renal or hematopoietic stem cell transplantation may cause serious complications, including BKV-associated nephropathy (BKVAN), ureteric stenosis, or hemorrhagic cystitis. Implementation of more potent immunosuppression and increased posttransplant surveillance has resulted in a higher incidence of BKVAN. Antiviral immunity plays a crucial role in controlling BKV replication, and our increasing knowledge about host-virus interactions has led to the development of improved diagnostic tools and clinical management strategies. Currently, there are no effective antiviral agents for BKV infection, and the mainstay of managing reactivation is reduction of immunosuppression. Development of immune-based therapies to combat BKV may provide new and exciting opportunities for the successful treatment of BKV-associated complications.

5 July 2018 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
CSCorey Smith
Corey Smith
LBLeone Beagley
Leone Beagley
SRSweera Rehan
Sweera Rehan
MNMichelle A Neller
Michelle A Neller
PCPauline Crooks
Pauline Crooks
RKRajiv Khanna
Rajiv Khanna
Opportunistic infections including cytomegalovirus (CMV) are a major cause of morbidity and mortality in solid organ transplant (SOT) recipients. The recurrent and protracted use of antiviral drugs with eventual emergence of drug resistance represents a significant constraint to therapy. Although adoptive T-cell therapy has been successfully used in hematopoietic stem cell transplant recipients, its extension to the SOT setting poses a considerable challenge because of the inhibitory effects of immunosuppressive drugs on the virus-specific T-cell response in vivo and the perceived risk of graft rejection. In this prospective study, 22 SOT recipients (13 renal and 8 lung and 1 heart transplants) with recurrent or ganciclovir-resistant CMV infection were recruited, and 13 of them were treated with in vitro-expanded autologous CMV-specific T cells. These patients were monitored for safety, clinical symptoms, and immune reconstitution. Autologous CMV-specific T-cell manufacture was attempted for 21 patients, and was successful in 20. The use of this adoptive immunotherapy was associated with no therapy-related serious adverse events. Eleven (84%) of the 13 treated patients showed improvement in symptoms, including complete resolution or reduction in DNAemia and CMV-associated end-organ disease and/or the cessation or reduced use of antiviral drugs. Furthermore, four of these patients showed coincident increased frequency of CMV-specific T cells in peripheral blood after completion of T-cell therapy. The data presented here demonstrate for the first time the clinical safety of CMV-specific adoptive T-cell therapy and its potential therapeutic benefit for SOT recipients with recurrent and/or drug-resistant CMV infection or disease. ACTRN12613000981729.

15 September 2008 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
GFGang Feng
Gang Feng
WGWenda Gao
Wenda Gao
TSTerry B. Strom
Terry B. Strom
MOMohamed Oukka
Mohamed Oukka
RFRoss S. Francis
Ross S. Francis
ABAndrew Bushell
Andrew Bushell
Interferon (IFN)‐γ was originally characterized as a pro‐inflammatory cytokine with T helper type 1‐inducing activity, but subsequent work has demonstrated that mice deficient in IFN‐γ or IFN‐γ receptor show exacerbated inflammatory responses and accelerated allograft rejection, suggesting that IFN‐γ also has important immunoregulatory functions. Here, we demonstrate that ex vivo IFN‐γ conditioning of CD4 T cells driven by allogeneic immature dendritic cells (DC) results in the emergence of a Foxp3+ regulatory T‐cell (Treg)‐ dominant population that can prevent allograft rejection. The development of this population involves conversion of non‐Treg precursors, preferential induction of activation‐induced cell death within the non‐Treg population and suppression of Th2 and Th17 responses. The suppressive activity of IFN‐γ is dependent on the transcription factor signal transducer and activator of transcription 1 and is mediated by induced nitric oxide. These data indicate not only how IFN‐γ could be used to shape beneficial immune responses ex vivo for possible cell therapy but also provide some mechanistic insights that may be relevant to exacerbated inflammatory responses noted in several autoimmune and transplant models with IFN‐γ deficiency.

8 December 2010 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
RFRoss S. Francis
Ross S. Francis
GFGang Feng
Gang Feng
TTThanyalak Tha‐In
Thanyalak Tha‐In
ILIan S. Lyons
Ian S. Lyons
KWKathryn J. Wood
Kathryn J. Wood
ABAndrew Bushell
Andrew Bushell
Naturally occurring FOXP3+CD4+ Treg have a crucial role in self‐tolerance. The ability to generate similar populations against alloantigens offers the possibility of preventing transplant rejection without indefinite global immunosuppression. Exposure of mice to donor alloantigens combined with anti‐CD4 antibody induces operational tolerance to cardiac allografts, and generates Treg that prevent skin and islet allograft rejection in adoptive transfer models. If protocols that generate Treg in vivo are to be developed in the clinical setting it will be important to know the origin of the Treg population and the mechanisms responsible for their generation. In this study, we demonstrate that graft‐protective Treg arise in vivo both from naturally occurring FOXP3+CD4+ Treg and from non‐regulatory FOXP3−CD4+ cells. Importantly, tolerance induction also inhibits CD4+ effector cell priming and T cells from tolerant mice have impaired effector function in vitro. Thus, adaptive tolerance induction shapes the immune response to alloantigen by converting potential effector cells into graft‐protective Treg and by expanding alloreactive naturally occurring Treg. In relation to clinical tolerance induction, the data indicate that while the generation of alloreactive Treg may be critical for long‐term allograft survival without chronic immunosuppression, successful protocols will also require strategies that target potential effector cells.

28 January 2016 in Nephrology
Verified
Journal Article
Closed access
PDF file
RERobert Ellis
Robert Ellis
DSDavid M Small
David M Small
David VeseyDavid Vesey
David Vesey
DJDavid W Johnson
David W Johnson
RFRoss Francis
Ross Francis
CMChristudas Morais
Christudas Morais

18 May 2011 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
GFGang Feng
Gang Feng
SNSatish N. Nadig
Satish N. Nadig
LBLiselotte Bäckdahl
Liselotte Bäckdahl
SBStephan Beck
Stephan Beck
RFRoss S. Francis
Ross S. Francis
ABAndrew Bushell
Andrew Bushell
Regulatory T cells (Tregs) manipulated ex vivo have potential as cellular therapeutics in autoimmunity and transplantation. Although it is possible to expand naturally occurring Tregs, an attractive alternative possibility, particularly suited to solid organ and bone marrow transplantation, is the stimulation of total T cell populations with defined allogeneic antigen-presenting cells (APCs) under conditions that lead to the generation or expansion of donor-reactive, adaptive Tregs. Here we demonstrate that stimulation of mouse CD4+ T cells by immature allogeneic dendritic cells combined with pharmacological inhibition of phosphodiesterase 3 (PDE) resulted in a functional enrichment of Foxp3+ T cells. Without further manipulation or selection, the resultant population delayed skin allograft rejection mediated by polyclonal CD4+ effectors or donor-reactive CD8+ T cell receptor transgenic T cells and inhibited both effector cell proliferation and T cell priming for interferon-γ production. Notably, PDE inhibition also enhanced the enrichment of human Foxp3+ CD4+ T cells driven by allogeneic APCs. These cells inhibited T cell proliferation in a standard in vitro mixed lymphocyte assay and, moreover, attenuated the development of vasculopathy mediated by autologous peripheral blood mononuclear cells in a functionally relevant humanized mouse transplant model. These data establish a method for the ex vivo generation of graft-reactive, functional mouse and human Tregs that uses a clinically approved agent, making pharmacological PDE inhibition a potential strategy for Treg-based therapies.